NASDAQ: HSIC | Healthcare / Medical Distribution / USA |
76.50 | +1.08 | +1.43% | Vol 202.77K | 1Y Perf -0.15% |
Aug 10th, 2022 00:38 DELAYED |
BID | 76.48 | ASK | 76.52 | ||
Open | 75.94 | Previous Close | 75.42 | ||
Pre-Market | - | After-Market | - | ||
- -% | - - |
Target Price | 86.44 | Analyst Rating | Hold 2.83 | |
Potential % | 13.02 | Finscreener Ranking | ★+ 43.72 | |
Insiders Trans % 3/6/12 mo. | -100/-88/-89 | Value Ranking | ★★+ 48.02 | |
Insiders Value % 3/6/12 mo. | -100/-99/-99 | Growth Ranking | ★★★ 52.04 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-99/-99 | Income Ranking | — - | |
Price Range Ratio 52W % | 27.86 | Earnings Rating | Sell | |
Market Cap | 10.41B | Earnings Date | 2nd Aug 2022 | |
Alpha | -0.01 | Standard Deviation | 0.08 | |
Beta | 0.74 |
Today's Price Range 75.6676.52 | 52W Range 70.2592.68 | 5 Year PE Ratio Range 9.0029.60 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 1.18% | ||
1 Month | -1.90% | ||
3 Months | -10.81% | ||
6 Months | -1.14% | ||
1 Year | -0.15% | ||
3 Years | 19.66% | ||
5 Years | -9.85% | ||
10 Years | 95.49% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 11.43 | |||
ROE last 12 Months | 19.11 | |||
ROA (5Y Avg) | 4.22 | |||
ROA last 12 Months | 8.18 | |||
ROC (5Y Avg) | 10.45 | |||
ROC last 12 Months | 14.46 | |||
Return on invested Capital Q | 3.91 | |||
Return on invested Capital Y | 3.30 | |||
Assets Turnover | 1.30 | |||
Receivables Turnover | 7.10 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
16.60 | ||||
2.94 | ||||
1.09 | ||||
14.60 | ||||
43.20 | ||||
5.26 | ||||
116.10 | ||||
26.02 | ||||
11.66B | ||||
Forward PE | 14.44 | |||
PEG | 1.42 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.70 | ||||
1.80 | ||||
0.23 | ||||
0.34 | ||||
31.40 | ||||
Leverage Ratio | 2.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
29.70 | ||||
6.90 | ||||
8.60 | ||||
5.90 | ||||
5.26 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
9.69B | ||||
70.18 | ||||
2.27 | ||||
-1.29 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | 1.12 | 1.16 | 3.57 |
Q01 2022 | 1.21 | 1.30 | 7.44 |
Q04 2021 | 0.90 | 1.07 | 18.89 |
Q03 2021 | 0.94 | 1.10 | 17.02 |
Q02 2021 | 0.95 | 1.11 | 16.84 |
Q01 2021 | 0.83 | 1.24 | 49.40 |
Q04 2020 | 0.96 | 1.00 | 4.17 |
Q03 2020 | 0.72 | 1.03 | 43.06 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 1.12 | -2.61 | Negative |
9/2022 QR | 1.18 | -3.28 | Negative |
12/2022 FY | 4.86 | 0.00 | - |
12/2023 FY | 5.22 | 0.00 | - |
Next Report Date | - |
Estimated EPS Next Report | 1.12 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | 11.70 |
Volume Overview | |
---|---|
Volume | 202.77K |
Shares Outstanding | 136.11K |
Shares Float | 121.71M |
Trades Count | 5.35K |
Dollar Volume | 15.44M |
Avg. Volume | 843.48K |
Avg. Weekly Volume | 964.67K |
Avg. Monthly Volume | 771.78K |
Avg. Quarterly Volume | 794.00K |
Henry Schein Inc. (NASDAQ: HSIC) stock closed at 75.42 per share at the end of the most recent trading day (a -1.21% change compared to the prior day closing price) with a volume of 700.15K shares and market capitalization of 10.41B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Distribution industry, Healthcare sector and employs 21000 people. Henry Schein Inc. CEO is Stanley M. Bergman.
The one-year performance of Henry Schein Inc. stock is -0.15%, while year-to-date (YTD) performance is -2.72%. HSIC stock has a five-year performance of -9.85%. Its 52-week range is between 70.25 and 92.68, which gives HSIC stock a 52-week price range ratio of 27.86%
Henry Schein Inc. currently has a PE ratio of 16.60, a price-to-book (PB) ratio of 2.94, a price-to-sale (PS) ratio of 1.09, a price to cashflow ratio of 14.60, a PEG ratio of 2.32, a ROA of 8.18%, a ROC of 14.46% and a ROE of 19.11%. The company’s profit margin is 5.26%, its EBITDA margin is 8.60%, and its revenue ttm is $9.69 Billion , which makes it $70.18 revenue per share.
Of the last four earnings reports from Henry Schein Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.12 for the next earnings report. Henry Schein Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Henry Schein Inc. is Hold (2.83), with a target price of $86.44, which is +13.02% compared to the current price. The earnings rating for Henry Schein Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Henry Schein Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Henry Schein Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.78, ATR14 : 1.92, CCI20 : -47.89, Chaikin Money Flow : 0.00, MACD : -0.64, Money Flow Index : 41.76, ROC : -2.10, RSI : 36.12, STOCH (14,3) : 33.94, STOCH RSI : 0.77, UO : 40.52, Williams %R : -66.06), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Henry Schein Inc. in the last 12-months were: Gerald A. Benjamin (Sold 22 978 shares of value $1 963 930 ), James P. Breslawski (Sold 14 816 shares of value $1 280 129 ), Kurt P. Kuehn (Sold 2 200 shares of value $189 134 ), Mark E. Mlotek (Sold 30 367 shares of value $2 541 496 ), Michael S. Ettinger (Sold 21 112 shares of value $1 788 046 ), Philip A. Laskawy (Sold 2 790 shares of value $245 297 ), Scott P. Serota (Buy at a value of $85 870), Stanley M. Bergman (Sold 60 000 shares of value $4 754 357 ), Walter Siegel (Sold 30 140 shares of value $2 500 714 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Hold | Hold | Hold |
Henry Schein is the largest wholesaler of dental and medical products to office-based practitioners. The company has been established for approximately 90 years and operates across nearly 30 distribution centers to offer hundreds of thousands of products to customers globally. Henry Schein also offers practice management products that include software products, technical, financial, and educational services. The company recently spun off its animal health business.
CEO: Stanley M. Bergman
Telephone: +1 631 843-5500
Address: 135 Duryea Road, Melville 11747, NY, US
Number of employees: 21 000
Tue, 17 May 2022 09:01 GMT Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS), Henry Schein (HSIC) and Roche Holding AG (OtherRHHVF)
- TipRanks. All rights reserved.Sun, 17 Apr 2022 12:47 GMT Henry Schein (HSIC) Receives a Buy from Robert W. Baird
- TipRanks. All rights reserved.Wed, 23 Mar 2022 12:37 GMT Robert W. Baird Believes Henry Schein (HSIC) Wont Stop Here
- TipRanks. All rights reserved.Wed, 16 Feb 2022 13:45 GMT Henry Schein (HSIC) Gets a Buy Rating from Barrington
- TipRanks. All rights reserved.Tue, 15 Feb 2022 14:44 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Henry Schein (HSIC) and Applied Genetic Technologies (AGTC)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.